Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy
Shots:
- The FIREFISH study involves assessing of Risdiplam in infants aged 1-7 mos. with Type 1 SMA
- The P-II FIREFISH study results: met its 1EPs i.e- the proportion of infants sitting without support for at least 5sec @12mos. of treatment- assessed by the Gross Motor Scale of BSID-III- consistent safety profile with no new safety signals
- Risdiplam is an investigational SMN2 splicing modifier for SMA- currently being evaluated in 4 multicenter studies and has received US FDA’s PR status with its expected approval by 24 May- 2019
Click here to read full press release/ article
Ref: GlobeNewswire | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com